

**IMAGIN MEDICAL INC.**  
**MANAGEMENT DISCUSSION & ANALYSIS**

**For the Six Months Ended March 31, 2019**

**Directors and Officers as of June 3, 2019**

**Directors:**

Robin Atlas  
Chris Bleck  
Ken Daignault  
Jim Hutchens  
John Vacha

**Officers:**

President & C.E.O. – Jim Hutchens  
C.F.O. & Secretary – John Vacha

**Contact Names:**

Jim Hutchens  
John Vacha

**Telephone Number:**

833-246-2446

**IMAGIN MEDICAL INC.**

**MANAGEMENT DISCUSSION & ANALYSIS**

For the Six Months Ended March 31, 2019

**1.1 Date of This Report**

**June 3, 2019**

This Management's Discussion & Analysis ("MD&A") of Imagin Medical Inc. for the six months ended March 31, 2019 has been prepared based on information available to us as of June 3, 2019. This discussion should be read in conjunction with the Condensed Interim Consolidated Financial Statements of the Company and notes attached thereto for the six months ended March 31, 2019 included herewith, all of which are available at the SEDAR website at [www.sedar.com](http://www.sedar.com).

*This MD&A includes certain statements that may be deemed "forward-looking statements". All statements in this discussion, other than statements of historical facts, that address activities and events or developments that the Company expects, are forward-looking statements. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in the forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include product development timing, government regulatory approvals, hospital reimbursement, continued availability of capital and financing and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Reported currency is stated in Canadian dollars.*

**1.2 Overall Performance**

*Description of Business*

Imagin Medical Inc. (formerly Expedition Mining Inc.) is incorporated in the Province of British Columbia and its previous principal business activity was the acquisition and exploration of resource properties. On February 9, 2016, the Company completed the acquisition of BSS Life Sciences Inc. ("BSS"). BSS holds the intellectual property rights to a proprietary imaging technology developed for extremely accurate visualization of cancers. In connection with the acquisition, the Company changed its name to Imagin Medical Inc. and now focuses on the research, develop and commercialization in the device/instrumentation medical technology industry.

*License Agreement*

By way of a Licence Agreement dated May 20, 2015, BSS was granted an exclusive, nontransferable, royalty-bearing license by Lawrence Livermore National Security, LLC (LLNS), to use LLNS's patents and intellectual property rights to manufacture and sell products and services pertaining to in-vivo imaging applications.

Under the License Agreement, BSS must:

- complete a commercial prototype by December 31, 2016 (First prototype completed);
- complete submissions for United States Food and Drug Administration (“FDA”) approval by December 31, 2017 (Not Completed and extended to Dec 31, 2019);
- achieve first commercial sales (“FCS”) in the United States within one year of achieving the FDA approval; and
- achieve gross cumulative sales revenues from the sales of licensed products of at least \$10,000,000 within the first three years of achieving FCS.

The sales requirements may be amended and/or extended at the written request of BSS to LLNS, based upon legitimate business reasons specified in reasonable detail in such written request.

BSS must pay certain fees to LLNS for the licence, being (all amounts are in US dollars):

- (i) a nonrefundable issue fee of \$100,000 payable as follows:
  - \$10,000 upon the date of execution of the Agreement (June 22, 2015; paid);
  - \$30,000 by November 22, 2015 (paid);
  - \$30,000 by January 22, 2016 (paid); and
  - \$30,000 by March 22, 2016 (paid).
- (ii) an earned royalty of 3% of net sales, subject to minimum annual royalties of:

| <b>Calendar year</b> | <b>Minimum annual royalty</b> | <b>Due date</b>          |
|----------------------|-------------------------------|--------------------------|
| 2017                 | \$5,000                       | February 28, 2017 (paid) |
| 2018                 | \$10,000                      | February 28, 2018 (paid) |
| 2019                 | \$10,000                      | February 28, 2019 (paid) |
| 2020 and thereafter  | \$25,000                      | February 28 of each year |

- (iii) a nonrefundable U.S. Maintenance Patent Fee of \$45,000 to be paid as follows:
  - \$15,000 on or before February 28, 2016 (paid);
  - \$15,000 on or before February 28, 2019 (paid); and
  - \$15,000 on or before February 28, 2023

### ***The Technology***

Imagin Medical is a surgical imaging company focused on establishing a new standard of care in visualizing cancer during minimally invasive surgeries (MIS). The Company believes its first product, the i/Blue Imaging™ System, will dramatically improve surgeons’ ability to visualize cancerous cells by producing higher-quality images more quickly compared with current methods. Based on advanced optics and light sensors, the i/Blue Imaging System employs patented ultrasensitive imaging technology, offers easy-to-use viewing options for more accurate resection of cancerous cells. The Company’s initial focus is bladder cancer.

The i/Blue Imaging System is a device external to the body that attaches to an endoscope to emit both white and blue light during MIS. When used in combination with contrast agents, cancerous cells, including premalignant lesions and tumor tissue along the margins, begin to fluoresce within an hour or less. The i/Blue Imaging System provides the option to display, in real-time, the white and blue light images side-by-side or alternatively, a composite image that places the cancer into context within the bladder. This advancement eliminates the surgeon's need to switch back and forth between the white and blue light images when locating and then resecting the cancer.

Imagin's i/Blue Imaging System is comprised of two key, state-of-the-art components:

- The i/Blue Control Unit: contains dual high-intensity light source, camera controller and power supply modules that allow simultaneous displays of white and blue light illumination in the interior of the bladder.
  
- Dual Camera Handpiece: includes sophisticated optical filters that split the image into white and blue light channels, allowing simultaneous display of corresponding images on the surgical monitor. This patented technology can be seamlessly adapted to most endoscopes on the market today and offers multiple real-time viewing options/images that better enable the surgeon to visualize and resect the cancer.

#### *Benefits of the i/Blue Imaging System*

- Enables surgeons to better visualize and resect the cancer
  - No toggling back and forth between images
  - Option for side-by-side or composite white and blue light images
  - Shows cancer in context
  - Adapts seamlessly to most types of endoscopes on the market
  - Potentially visualizes the cancer more rapidly
  - Appropriate for physicians' offices

#### *Future Development - Disruptive Technology /Multiple Markets*

Imagin intends to build on the i/Blue technology, which currently works with hexaminolevulinate hydrochloride (HAL), and adapt it to other U.S. Food and Drug Administration (FDA)-approved contrast agents, such as Indocyanine green (ICG). These additional products will expand Imagin's market potential, facilitating entry into multiple endoscopic procedures, such as laparoscopic (general and gynecology), colorectal and thoracic.

Imagin is actively pursuing opportunities to acquire or distribute additional products such as disposable scopes, cancer biopsy devices and other products to complement its portfolio.

## ***The Strategy***

Imagin will differentiate the MIS surgical imaging market by focusing on state-of-the-art, easy-to-use, practical and cost-effective cancer visualization systems.

The Company's initial target market is surgical bladder cancer treatment, with expansion of bladder cancer fluorescence imaging and biopsy to be conducted in physicians' offices.

Once the i/Blue Imaging System is commercially available for urological indications, Imagin will focus on expanding the product platform from bladder cancer to laparoscopic (abdominal), colorectal, thoracic and other medical procedures. The Company will partner with manufacturers of contrast agents that are already FDA-approved or in their final phase (Phase III) of FDA approval.

To prepare for commercialization, the Company is initiating marketing programs comprised of participation in trade shows and focus groups along with the development of physician champions and Centers of Excellence. The Company will build on current relationships with key independent sales representatives currently successful the urology marketplace.

As previously mentioned, Imagin plans to add complementary products to expand its product portfolio. Because the i/Blue technology is adaptable to most endoscopes currently on the market, the Company will be of strategic interest to existing dominant endoscope manufacturers.

## ***Intellectual Property***

The Company, through its wholly owned subsidiary (BSS Life Sciences) has secured an exclusive license from Lawrence Livermore National Security, LLC (LLNS) to commercialize the technology invented by Dr. Stavros Demos. This license agreement includes three issued patents and one pending patent application on technology related to exclusive spectroscopic imaging for cancer and other medical applications. These include:

1. Issued U.S. Patent 7,149,567 - Near-Infrared Spectroscopic Tissue Imaging for Medical Applications
2. Issued U.S. Patent 7,257,437 - Autofluorescence Detection and Imaging of Bladder Cancer Realized Through a Cystoscope.
3. Issued U.S. Patent 8,285,015 - Simultaneous Acquisition of Differing Image Types
4. Pending U.S. Patent Application No. 13/601,918 - Simultaneous Acquisition of Differing Image Images

Based on product refinement and development since the completion of the University of Rochester study, Imagin is filing additional patent applications that the company anticipates will broaden its intellectual property portfolio.

## ***Product Development Plan and Timing***

Imagin's product development partner, Optel, has extensive experience integrating optics, mechanics, electronics and software into user-friendly, cost-effective products and has been instrumental in the Company's reaching its design goals of providing higher-quality images more quickly using software that allows multiple images to be displayed simultaneously.

Results from the study conducted at the University of Rochester Medical Center prompted Optel to re-examine the i/Blue technology concept. The original prototype was a self-contained unit with a 36"x 32" footprint. Optel was able to take advantage of state-of-the-art optical and electro-phonic components to extensively redesign the prototype. The result is a very innovative approach that splits the functions of the i/Blue unit into two separate units. This modular concept allows more flexibility and has resulted in a 90% reduction in the size of the system while conforming to all FDA specifications. Although this redesign added several months to Imagin's development plan, the Company believes it has resulted in a higher performing, cost-effective product that will be embraced by the marketplace.

The Company has completed a major product development milestone with the announcement that of functional units are now available for testing. Following the typical product development path for a new medical technology, the Company is working to move the i/Blue Imaging System through various progressive stages: original design, proof of principle prototype, functional system, pilot production, product validation and, finally, realized product for commercialization. The Company continues to believe that the imaging quality and cost reduction goals for the i/Blue Imaging System will be achieved. The product will be highly manufacturable and cost effective, with a modular design that will become a basic platform for Imagin's current and future imaging systems and applications.

At Imagin's request, the Company met with the FDA in Q1 2019 to proactively discuss the i/Blue Imaging System's regulatory path and the potential need for a clinical study. The content and feedback from the meeting will be instrumental as the Company continues to refine its regulatory strategy. Discussions with the FDA will be ongoing. Imagin will ensure that the i/Blue Imaging System will be in compliance with the requirements of the FDA, Good Manufacturing Practices (GMP), European medical device standard ISO 13485, and other international compliance requirements.

## ***Highlights from Oct 1, 2018 up to the date of this report***

The Company announced the following:

- welcomed world-renowned bladder cancer expert Dr. Ashish M. Kamat to its Scientific Board of Advisors
- announced that it reached the first step of a major product development milestone with completion of the i/Blue Imaging System's Functional Unit

- announced the Q1 2019 Fiscal results and completed it's first Investor Conference call to announce and discuss these results
- announced new presentation on the Company website
- reported fiscal year end 2018 results
- announced results of the Annual Meeting of Shareholders
- commented on recent promotional activity pursuant to OTC Markets request
- announced receipt of approximately \$1 million from the Exercise of Warrants
- announced the appointment of Chris Bleck to the Board of directors and the resignation of Steve Chan.
- received gross proceeds of \$524,454 from the exercise of 5,205,840 previously issued share purchase warrants and finders' warrants.
- announced that all matters put forward before the shareholders, as set out in the Company's management information circular dated November 15, 2018, were approved by the requisite majority of votes cast at the Annual General Meeting.
- at the date of this report, the Company currently has 139,060,278 issued and outstanding Shares; 17,919,820 Finance Warrants; 1,117,110 finders' warrants; and 10,100,000 incentive stock options.

### 1.3 **Selected Annual Information**

The highlights of financial data for the Company for the two most recently completed financial years are as follows:

|                                | <u>Sept. 30, 2018</u> | <u>Sept. 30, 2017</u> |
|--------------------------------|-----------------------|-----------------------|
| (a) Loss before other items    |                       |                       |
| (i) Total loss                 | \$4,988,339           | \$1,377,537           |
| (ii) Loss per share – basic    | \$0.05                | \$0.03                |
| (iii) Loss per share – diluted | \$0.05                | \$0.03                |
| (b) Net loss                   |                       |                       |
| (i) Total loss                 | \$7,958,086           | \$1,542,102           |
| (ii) Loss per share – basic    | \$0.07                | \$0.03                |
| (iii) Loss per share – diluted | \$0.07                | \$0.03                |
| (c) Total assets               | \$6,171,702           | \$389,644             |

### 1.4 **Results of Operations**

#### *Discussion of Operations and Financial Condition*

The following should be read in conjunction with the condensed interim consolidated financial statements for the six months ended March 31, 2019 and notes attached hereto.

During the six months ended March 31, 2019, the Company reported a net loss of \$1,937,656 (\$3,989,309 – March 31, 2018). The Company incurred the following major expenditures:

1. Business Development - \$47,846 (March 31, 2018 – Nil). Business Development efforts focused on market research and competitive analysis in advance of commercialization as well as possible partnership/product opportunities.
2. Consulting fees – Total \$334,797 (March 31, 2018 - \$702,926; decreased by \$368,129). Consulting fees consists of:
  - Marketing and Investor Relations – \$296,650 (March 31, 2018 - \$702,926; decreased by \$406,276): In the previous year the Company engaged numerous consultants to provide services primarily related to raising capital and public relations, specifically, internet marketing, research reports, news and press releases and their distribution. The Company continues with its ongoing communications and marketing programs to efficiently increase awareness of the progress of the Company, allowing the Company to continue to maintain its existing cash for product development and commercialization. However, in the current year, there have been no expenses related to the raising of capital which is the primary reason for the decrease from the prior period.
  - Sales & Marketing - \$18,299 (March 31, 2018 – Nil): The Company engaged consultants to provide services related to customer feedback and marketing.
  - OTC Listing - \$19,847 (March 31, 2018 – Nil) – The Company incurred application fees related to the listing with the OTC.
3. Legal & accounting – Total \$235,489 (March 31, 2018 - \$92,666; increased by \$142,823). In the second quarter of the previous fiscal year, the Company hired John Vacha as the new Chief Financial Officer. Jorge Avelino, the former Chief Financial Officer continues to work with the Company assisting with the regulatory and accounting functions.
4. Management fees – Total \$348,818 (March 31, 2018 - \$1,329,464; decreased by \$980,646). In the second quarter of the previous fiscal year, the Board of Directors approved an annual salary of US\$450,000 for the President and CEO. However, the decrease resulted from the bonus shares (\$1,175,000) granted in the previous fiscal year.
5. Product Development – Total \$739,804 (March 31, 2018 - \$211,471; increased by \$582,333). The increase is primarily related to the work performed by outsourced design and engineering, regulatory, fda, legal and quality consultants for the design and development of the i/Blue system and associated fda & regulatory plans.

The Company also reported receivables and prepaids for a total amount of \$101,078 (September 30, 2018 - \$211,141). The amount is broken down as follows:

|                           |    | 31-Mar-19 | 30-Sep-18 |
|---------------------------|----|-----------|-----------|
| GST Receivable            | \$ | 6,089     | 7,398     |
| Interest Receivable (GIC) |    | 23,939    | 19,560    |
| Prepaid expenses **       |    | 71,050    | 174,183   |
| Trust account             |    | -         | 10,000    |
|                           | \$ | 101,078   | 211,141   |

## **Shareholders Communication and Travel**

For the period ended March 31, 2019, the Company reported shareholder communication and travel expenses totaling \$115,184 (March 31, 2018 - \$62,225) and broken down as follows:

|                             | 31-Mar-19         | 31-Mar-18        |
|-----------------------------|-------------------|------------------|
| Communication & information | \$ 10,467         | \$ 9,119         |
| Conferences                 | 36,620            | 5,365            |
| Press releases              | 20,574            | 10,728           |
| Telephone & website         | 1,865             | 11,031           |
| Travel & entertainment      | 45,658            | 25,982           |
|                             | <b>\$ 115,184</b> | <b>\$ 62,225</b> |

## **Summary of Quarterly Results**

The following is a summary of the Company's financial results for the eight most recently completed quarters:

|           | <b><u>Q1 31-Mar-19</u></b> | <b><u>Q1 31-Dec-18</u></b> | <b><u>Q4 30-Sep-18</u></b> | <b><u>Q3 30-Jun-18</u></b> |
|-----------|----------------------------|----------------------------|----------------------------|----------------------------|
|           | <b>IFRS</b>                | <b>IFRS</b>                | <b>IFRS</b>                | <b>IFRS</b>                |
| Net loss  | (926,070)                  | (1,011,586)                | (2,217,112)                | (1,751,665)                |
| Per Share | (0.5)                      | (0.5)                      | (2.0)                      | (1.5)                      |
|           | <b><u>Q2 31-Mar-18</u></b> | <b><u>Q1 31-Dec-17</u></b> | <b><u>Q4 30-Sep-17</u></b> | <b><u>Q3 30-Jun-17</u></b> |
|           | <b>IFRS</b>                | <b>IFRS</b>                | <b>IFRS</b>                | <b>IFRS</b>                |
| Net loss  | (2,718,811)                | (1,270,498)                | (373,798)                  | (298,242)                  |
| Per Share | (2.5)                      | (1.5)                      | (0.01)                     | (0.005)                    |

On February 9, 2016, the Company completed the acquisition of BSS Life Sciences ("BSS"). In connection with the closing, the Company issued 26,500,000 common shares to the shareholders of BSS (see note 10). As a result of the exchange, the transaction resulted in a reverse asset acquisition. Accordingly, BSS will be considered the continuing entity for accounting and financial reporting purposes and the Company, the continuing public company, being the corporation acquired.

### ***Discussion***

#### **Six months ended March 31, 2019:**

For the six months ended March 31, 2019, please refer to Section 1.4 Results of Operations.

## **1.5 Liquidity**

The Company has no current operating income or cash flow. In management's view, given the nature of the Company's operations, the most relevant financial information relates primarily to current liquidity, solvency and planned expenditures. The Company's financial success will be dependent on continuing to raise operating capital and successful clinical

trials that validate the company's technology and such activities may take time to complete and the amount of resulting income is difficult to determine.

In the previous fiscal year, the Company completed two non-brokered private placements through the issuance of 20,000,000 units for gross proceeds of \$1,000,000 and 17,919,820 units for gross proceeds of \$3,942,360. In addition, 31,539,580 finance warrants and finders' warrants, with prices ranging from \$0.10 to \$0.35 for total proceeds of \$4,227,414.

In the six months ended March 31, 2019, an additional 5,205,840 finance warrants and finders' warrants, with prices ranging from \$0.10 to \$0.16 for total proceeds of \$524,454.

As at March 31, 2019, the Company had \$4,511,888 in cash and \$101,078 in accounts receivable and prepaid expenses. The Company currently has no revenue being generated from its i/Blue system for the early detection of cancer. Depending on the final FDA device classifications, schedule and marketing clearance, the Company is planning to initiate the commercialization of the i/Blue Imaging System late in calendar year 2020 and believes it will achieve rapid revenue growth.

The Company's historical capital needs have been met by equity subscriptions. On March 31, 2019, the Company had working capital of \$4,420,085 (September 30, 2018 – working capital of \$5,856,202).

#### Cash and cash equivalents

|                                   | <b>31-Mar-19</b>    | <b>30-Sep-18</b>    |
|-----------------------------------|---------------------|---------------------|
| Cash deposits                     | \$ 511,888          | \$ 2,318,840        |
| Guaranteed investment certificate | 4,000,000           | 3,500,000           |
| Total cash and cash equivalents   | <b>\$ 4,511,888</b> | <b>\$ 5,818,840</b> |

#### Credit Risk

Credit risk arises from cash held with banks and financial institutions. The maximum exposure to credit risk is equal to the carrying value of the financial assets. The Company's cash is held with a Canadian bank.

#### Currency Risk

Currency risk is the risk to the Company's earnings that arises from fluctuations of foreign exchange rates and the degree of volatility of these rates. The Company faces certain foreign exchange risks related to expenses incurred in U.S. dollars, a currency which may appreciate against the Canadian dollar, the Company's reporting currency. Additionally, net working capital balances denominated in non-reporting currencies are also subject to fluctuations in value. The Company mitigates these threats by limiting its exposure to such balances where their expenditure in the same non-reporting currency is not imminent.

#### Commitments

The Company has certain commitments related to the license agreement with Lawrence Livermore National Security. Please refer to Sections 1.2 Overall Performance – License Agreement.

## **1.6 Capital Resources**

The Company's capital resources is fixed assets (computers & office equipment) with a book value of \$1,193 September 30, 2018 - \$1,403).

## **1.7 Off Balance Sheet Arrangements**

There are no off-balance sheet arrangements to which the Company is committed.

## **1.8 Second Quarter**

The second quarter result does not differ significantly from other quarters.

## **1.9 Transactions with Related Parties**

During the six months ended March 31, 2019, the Company paid or accrued \$590,394 (March 31, 2018) - \$1,380,188) to directors and officers or companies controlled by directors and officers of the Company, for management, accounting, and directors fees incurred by the Company.

|                 |           | <b>31-Mar-19</b> | <b>31-Mar-18</b> |
|-----------------|-----------|------------------|------------------|
| Management fees | \$        | 348,818          | 1,329,464        |
| Accounting fees |           | 187,730          | 36,974           |
| Consulting fees |           | 47,846           | -                |
| Directors fees  |           | 6,000            | 8,750            |
| <b>Total</b>    | <b>\$</b> | <b>590,394</b>   | <b>1,380,199</b> |

During the previous fiscal year, the Company issued 5,000,000 shares to the President as a management bonus. These shares had a deemed value of \$1,175,000.

During the six months ended March 31, 2019, the Company did not grant any stock options (March 31, 2018 – 1,200,000).

Included in accounts payable are fees and expenses due to directors and officers in the amount of \$6,000 (September 30, 2018 - \$14,776), which are non-interest bearing, unsecured, and payable on demand. Fair value cannot be reliably determined.

## **1.10 Proposed Transactions**

N/A

## **1.11 Critical Accounting Estimates**

In preparing financial statements, management has to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses. Based on historical experience, current conditions and expert advice, management makes assumptions that are believed to be reasonable under the circumstances. These estimates and assumptions form the basis for judgments about the carrying value of assets and liabilities and reported amounts for revenues and expenses. Different assumptions would result in different estimates and actual results may differ from results based on these estimates. These

estimates and assumptions are also affected by management’s application of accounting policies. Critical accounting estimates are those that affect the consolidated financial statements materially and involve a significant level of judgment by management.

### 1.12 **Financial and Other Instruments**

The carrying value of cash and cash equivalents, marketable securities, accounts receivable, accounts payable and due from (to) related parties approximate their fair values due to the short maturity of those instruments.

### 1.13 **Other**

Disclosure of Outstanding Share Capital: June 3, 2019

|               | <u>Number</u>      |
|---------------|--------------------|
| Common Shares | <u>139,060,278</u> |

Disclosure of Outstanding Stock Options: June 3, 2019

|                         | <u>Number</u>     |
|-------------------------|-------------------|
| Incentive Stock Options | <u>10,100,000</u> |

Disclosure of Outstanding Share Purchase Warrants: June 3, 2019

|               | <u>Number</u>      |
|---------------|--------------------|
| Warrants      | <u>19,036,930</u>  |
| Fully diluted | <u>168,197,208</u> |

### **Disclosure Controls and Procedures**

It should be noted that pursuant to Multilateral Instrument 52-511 (adopted by the British Columbia Securities Commission on November 23, 2007), that the officers of the Company are no longer required to certify the effectiveness of disclosure controls and procedures used by the Company, as was required in previous filings under National Instrument 52-109. Accordingly, the new forms of certificate to be signed by the Company’s Chief Executive Officer and Chief Financial Officer contain the following Note to Reader:

In contrast to the certificate required under National Instrument 52-109 Certification of Disclosure in Issuers’ Annual and Filings (NI 52-109), this Venture Issuer Basic Certificate does not include representations relating to the establishment and maintenance of disclosure controls and procedures (DC&P) and internal control over financial reporting (ICFR), as defined in NI 52-109. In particular, the certifying officers filing this certificate are not making any representations relating to the establishment and maintenance of:

- (i) controls and other procedures designed to provide reasonable assurance that information required to be disclosed by the issuer in its annual filings, filings or other reports filed or submitted under securities legislation is recorded, processed, summarized and reported within the time periods specified in securities legislation; and
- (ii) a process to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with the issuer’s GAAP.

The issuer's certifying officers are responsible for ensuring that processes are in place to provide them with sufficient knowledge to support the representations they are making in this certificate.

Investors should be aware that inherent limitations on the ability of certifying officers of a venture issuer to design and implement on a cost-effective basis DC&P and ICFR as defined in NI 52-109 may result in additional risks to the quality, reliability, transparency and timeliness of and annual filings and other reports provided under securities legislation.

Additional information relating to the company is on SEDAR at [www.sedar.com](http://www.sedar.com).